Articles Tập 67 Số CĐ14-HNKH Hội Hóa sinh Y học Việt Nam 12/09/2026

SERUM VITAMIN D LEVELS IN PATIENTS WITH PRIMARY BONE TUMORS AND BONE METASTASES AT K HOSPITAL

Dieu Thi Thuy Chuyen, Phung Ngoc Hue, Nguyen Thi Phuong Thao, Vuong Thi Ngan
DOI: 10.52163/yhc.v67iCD14.6450
0 Views
0 Downloads
Abstract

Background: Vitamin D plays an important role in bone metabolism and cancer biology. However, plasma vitamin D status in patients with bone cancer in Vietnam has not been well studied.

Objectives: To determine plasma vitamin D levels and evaluate their association with biochemical, immunological markers of bone metabolism in patients with bone cancer.

Subject and Methods: A cross-sectional study was conducted on 93 patients with bone cancer, including 52 primary bone tumors and 41 cases of bone metastases. Plasma 25-hydroxyvitamin D [25-OH)D], calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase (ALP) were measured and statistically analyzed.

Results: The mean of plasma vitamin D level was 21.68 ± 7.36 ng/mL, with 86.03% of patients having vitamin D deficiency or insufficiency. Patients with bone metastases had significantly lower plasma vitamin D levels compared to those with primary bone tumors (19.03 ± 7.12 vs. 24.32 ± 6.84 ng/mL; p < 0.001) and a higher prevalence of severe deficiency (63.41% vs. 28.84%; p = 0.04). Plasma vitamin D levels tended to decrease with advancing disease stage. No significant correlations were found between plasma vitamin D levels and calcium, phosphorus, PTH, or ALP (p > 0.05).

Conclusions: Vitamin D deficiency is highly prevalent in patients with bone cancer (86.03%), particularly in those with bone metastases, and is not associated with biochemical markers of bone metabolism.

Keywords
Vitamin D; Bone tumors; Bone metastases; Cross-sectional study.
References
[1]
1.Holick M.F (2007). Vitamin D deficiency. N Engl J Med., 357(3): 266–281. Google Scholar
[2]
2.Feldman D., Krishnan A.V., Swami S., et al. (2014). The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer., 14(5): 342–357. Google Scholar
[3]
3.Garland C.F., Gorham E.D., Lipkin M., et al. (2006). The role of vitamin D in cancer prevention. Am J Public Health., 96(2): 252–261. Google Scholar
[4]
4.Coleman R.E (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res., 12(20 Suppl): 6243s–6249s. Google Scholar
[5]
5.Bộ Y tế (2020). Hướng dẫn điều trị một số bệnh ung bướu QĐ 1514/QĐ-BYT. Google Scholar
[6]
6.Holick M.F., Binkley N.C., Bischoff-Ferrri H.A., et al. (2011). Evaluation treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 96(7): 1911–1930. Google Scholar
[7]
7.Maier G.S., Horas K., Kurth A.A., et al. (2015). Prevalence of vitamin D deficiency in patients with bone metastases and multiple myeloma. Anticancer Res., 35(11): 6281–6286. Google Scholar
[8]
8.Horas K., Maier G., Jakob F., et al. (2017). High prevalence of vitamin D deficiency in patients with bone tumors. Cancer Invest., 35(9): 568–574. Google Scholar
[9]
9.Horas K., Holzapfel B.M., Jakob F., et al. (2018). The role of vitamin D and the vitamin D receptor in bone oncology. Osteologie., 27(3): 129–134. Google Scholar
[10]
10. Pilz S., Zittermann A., Trummer C., et al. (2019). Vitamin D testing and treatment: a narrative review of current evidence. Endocr Connect., 8(2): R27–R43. Google Scholar